Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

n

Picoplatin is an intravenous chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 800 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity or hearing loss, toxicities commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in patients with mHRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by regulatory authority for use in h
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...LIN, Mass., Nov. 26 PLC ... today that it has received full approval from the....S. pivotal trial to study the effectiveness of th...therapy in the prevention of Contrast-Induced Neph...C,s request to expand their investigation from the...
(Date:11/25/2008)...e-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (Na...d on,innovative oncology therapies, announced tod...es for its preclinical research programs in order ...e clinical development of picoplatin,its lead pr...cialization of,picoplatin in the treatment of sma...
(Date:11/24/2008)...o,s Pizza (NYSE: DPZ ), the,recognized world le...gh for,the kids of St. Jude Children,s Research H... campaign. Domino,s customers will have the opport...benefit the children of St. Jude.,Donations can b...ng online at, www.dominos.com . The campaign begi...
(Date:11/24/2008).../ -- Schering-Plough Corporation (NYSE: SGP ) to...tive adenosine2a receptor antagonist, met the prim...atients suffering from moderate to severe Parkinso...normal involuntary movements (dyskinesias). The t... 2008 R&D Update meeting being hosted for anal...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 1Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 2Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 3ATV Injuries on the Rise 6905 1ATV Injuries on the Rise 6905 2ATV Injuries on the Rise 6905 3Environmental exodus 1331 1Environmental exodus 1331 2Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 1Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 2
...sults Presented At ASCO -- , CHICAGO – June ... interferon alfa-2b in stage III melanoma had a,si...vival (RFS),according to the results of the large...stage III melanoma. Results of the Phase,III study...h and,Treatment of Cancer (EORTC) and supported by...
...007 - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmac..., today provided highlights of data presentations ...Oncology (ASCO) Annual,Meeting. Dacogen (decitabin...ncluding the presentation of efficacy data in olde...nd activity,observed in patients with refractory a...
Other Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
(Date:12/1/2008)...wire-USNewswire/ -- In recognition of World AIDS D...ching a mobile texting campaign to raise money for... a program of the Safe Blood for Africa Foundation...e million lives in Africa by 2011 by working in re...cal training. , , OMALI will be collecting...
(Date:12/1/2008)...RNewswire/ -- TOMS Shoes, the philanthropic,footw...e at TOMSshoes.com,encouraging people to Spend L...s, from November 20th through December 20th, TOMS ...irs of shoes to children in Ethiopia suffering,fr... by wearing shoes. By,purchasing a pair of shoes ...
(Date:12/1/2008)...rom U-M physician include economical options , ...SNewswire/ -- A bottle of cologne, a new pair of p...s to buy and wrap for the upcoming holiday season....y and beneficial to a loved one? Why not give the ... the holidays can be challenging, and this year, m...
(Date:12/1/2008)...swire/ -- TorreyPines Therapeutics, Inc.,(Nasdaq:... of NGX426, an,AMPA/kainate-type glutamate recept...ficant reduction in spontaneous pain, hyperalgesia...(pain resulting from normally non-painful stimuli ...ermal injections of capsaicin in,a human experime...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5
...terday about a surgeon Dr Jerome Blanchard who had.../ her with only a diseased one. The disciplinary...hurry removed the wrong kidney from a patient and ...did not bother to read her medical notes. Dr Jerom...
... price tag attached to it.Look at the United State...ealth and opportunity to its people;// but at a co...are 30% Americans who areover-weight or grossly ob...beingmade by China is going to land the country in...
...ude as many patients in the chronic disease manage...ter for Health Khaw Boon Wan who was addressing he...at chronic diseases are major causes of death and ...he past," Khaw said, adding that prompt treatment ...
...everages by the FDA (Food and Drug Administration)...nce of benzene//, a carcinogen in much higher amou...inking water. FDA had alerted these companies, an...te the soft drinks or had already done so. Though ...
Other Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:The Price Paid for New Lifestyle 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: